AstraZeneca PLC

Money comes mainly from direct sales of medicines, recognized once control passes to a wholesaler or distributor and after deducting rebates, returns and chargebacks negotiated with payers and health systems. A second, smaller stream comes from sharing in the profits, revenue or royalties that partner companies earn when they sell medicines developed jointly with it. Within product sales, oncology medicines and its biopharmaceuticals category together account for most of its income, with rare-disease treatments and other medicines making up a smaller remainder. Net income has been positive across each of the recent years for which figures are available.

Its scale rests on a broad base of already-approved medicines rather than any single product: it has many medicines that each generate substantial annual sales, so growth does not hinge on one drug's success. In the pattern common to companies that only earn once a medicine clears a long regulatory approval process, a product earns nothing during development and review, but once approved and protected from copying for a period, it can be sold at scale for years with manufacturing costs that do not rise in step with revenue. It also sits among a large group of other companies classified as running this same kind of approval-gated system, indicating this is a shared way of operating within its industry rather than something unique to it.

It depends on outside suppliers for many of its core physical inputs, including active pharmaceutical ingredients, packaging components, chemicals and excipients, some of which it says would be difficult to replace quickly or at all. Manufacture of the active ingredients themselves is mostly handled outside the company, alongside a smaller and growing share made internally. More broadly, it draws on a wider base of upstream industries than the range of industries it in turn supplies into, consistent with a business that consumes many kinds of specialized inputs to produce a narrower set of outputs.

A small number of wholesale distributors account for a large share of its direct product sales, based on its own disclosures, though it does not name them. More broadly, it reaches the market mainly through wholesalers, distributors and its own local marketing operations rather than selling directly to patients or health systems, and it feeds into a narrower set of downstream industries than the range it draws inputs from.

CompanyGraph cannot see which specific parts of this system rivals could or could not copy. What is visible is a position: a large number of other companies are classified as running this same kind of approval-gated system, so this way of operating is a shared structural shape across the industry rather than a rare one.

In its own account, the company points to several limits on how far it can grow: the difficulty of manufacturing medicines in sufficient quantity, government price controls and payer pressure on affordability, the erosion of intellectual-property protection over time, and a limited pool of people with the specialized skills its work requires. Consistent with the pattern common to companies that only earn once a medicine clears a long regulatory approval process, the risks it lists first in its own account concern delay or failure in that pipeline and approval process, ahead of manufacturing or commercial risks.

In its own account, the company names failure or delay in delivering its medicine pipeline and failure to meet regulatory or ethical approval requirements as the risks it lists first, ahead of pricing pressure, commercial execution and the supply of compliant medicines. It also discloses that a small number of wholesale customers each account for a large share of its direct product sales, and that it depends on outside suppliers for ingredients and packaging that it says can be difficult to substitute quickly or at all.

It operates under the oversight of national medicines regulators, which its own filings name as including the US Food and Drug Administration and the European Medicines Agency, governing how its medicines are approved, manufactured and distributed. Among the risks it lists first in its own account are pricing, affordability and access pressure from payers and governments, and competitive pressure from other treatments. It also discloses ongoing government inquiries and legal proceedings in the United States relating to pricing programs and payments to healthcare providers, and it names trade and tariff uncertainty as a live pressure, including an arrangement with the US government tied to shifting manufacturing onshore in exchange for temporary relief from tariffs.